Abstract
Purpose of the Review: As the number of cancer survivors increases due to early screening and modern (antineoplastic) treatments, cancer treatment associated cardiotoxicity (CTAC) is becoming an increasing health burden that affects survival and quality of life among cancer survivors. Thus, clinicians need to identify adverse events early, in an effort to take suitable measures before the occurrence of permanent or irreversible cardiac dysfunction. Recent Findings: Cardiac troponin (cTn) and B-type natriuretic peptide (BNP) have been proven to detect subclinical cardiotoxicity during antineoplastic treatment. As such, these cardio-specific biomarkers could predict which patients are at risk of developing CTAC even before the start of therapy. Nevertheless, there are inconsistent data from published studies, and the recommendations regarding the use of these biomarkers and their validity are mostly based on expert consensus opinion. Summary: In this review, we summarize available literature that evaluates biomarkers of CTAC, and we encourage strategies that integrate circulating biomarkers and cardiac imaging in identifying cancer patients that are at high risk.
Original language | English |
---|---|
Article number | 67 |
Journal | Current Oncology Reports |
Volume | 22 |
Issue number | 7 |
DOIs | |
Publication status | Published - 1 Jul 2020 |
Externally published | Yes |
Bibliographical note
Funding Information:This work is supported by the European Research Council (ERC CoG 818715, SECRETE-HF).
Publisher Copyright:
© 2020, The Author(s).